Risk for Psychiatric Illness Up in Early Postacute COVID-19 Phase
Risks for new-onset psychiatric diagnoses and anxiety disorders, but not mood disorders, increased in early postacute phase
Relative Risk for CVT Up After AZD1222 COVID-19 Vaccine
Relative rates of hospital contacts for coagulation disorder, cerebrovascular disease increased after AZD1222 vaccination
Global Seroprevalence of Tickborne Lyme Disease About 14.5 Percent
Factors associated with Bb seropositivity include male sex, age ≥50 years, residence in rural areas, suffering tick bites
Vaccine Effectiveness Against SARS-CoV-2 Infection Wanes Over Time
However, for all ages, vaccine effectiveness against severe COVID-19 high overall at 90 percent five months or longer after two doses
Pfizer, Moderna COVID-19 Shots Work for Children Under 5, FDA Says
On Wednesday, advisory panel will weigh whether the FDA should authorize the use of both the Pfizer and Moderna vaccines for young children
Herpes Zoster Not Linked to Increased Dementia Risk
Small reduction in risk for dementia seen after the first year for people with zoster versus general population comparators
Durability of mRNA-1273 Protection Against Symptomatic COVID-19 Examined
Among those receiving two doses, peak vaccine efficacy against symptomatic COVID-19 estimated to be 94.1 percent at 120 days after first dose
Text Messaging Intervention Does Not Improve COVID-19 Vaccine Uptake
No increase in vaccine uptake seen for individuals receiving text message versus phone calls or for behaviorally informed message content
Hospital Interns Spend Only 13.4 Percent of Time in Patient Rooms
Real-time locating systems may be used to improve the training experience, authors say
Monkeypox Cases Rising Slowly in the U.S., CDC Says
No deaths have been reported and no community transmission of monkeypox has yet been detected in any U.S. cities
